Selank
PeptideThe marked discrepancy arises because the community positively evaluates subjective, unblinded experiential reports [c1, c2, c3], whereas the medical evidence is based solely on two small Russian studies [s1, s5] and preclinical data [s4, s6, s7], with no independent Western RCTs.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Selank is a Russian heptapeptide with anxiolytic and nootropic properties, approved in Russia — but not a single independent Western RCT exists, and the entire clinical foundation rests on two small Russian studies. Community reports of anxiety reduction and calm focus without benzo-like sedation are compelling but unblinded self-reports are not evidence. In Germany, purchase and possession sit in a legal grey zone, and grey-market products without quality control represent the primary safety concern. Those seeking well-evidenced anxiolysis should consider ashwagandha or Rhodiola rosea first.
Description
Synthetic heptapeptide from Russia with anxiolytic and nootropic effects; modulates GABA, serotonin, and enkephalins; not approved in Germany [s1, s2].
Selank is a synthetic analogue of the endogenous immune peptide tuftsin (Thr-Lys-Pro-Arg) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences [s3]. The sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (heptapeptide) was designed to combine both nootropic and anxiolytic properties [s3, s4]. In Russian clinical trials, Selank was investigated in generalized anxiety disorder (GAD) and neurasthenia. Efficacy was compared to the benzodiazepine medazepam, with Selank demonstrating comparable anxiolytic effects and better tolerability [s1]. A further clinical study demonstrated immunomodulatory effects in patients with anxiety-asthenic disorders [s5]. Intranasal administration is the most common route of application, enabling rapid absorption via the nasal mucosa [s6]. Selank is rapidly metabolized, which complicates detection in plasma [s6]. In the biohacking community, Selank is primarily discussed for anxiety reduction, cognitive support, and as an alternative to benzodiazepines [c1, c2]. Outside Russia and CIS countries, regulatory approval is entirely absent [s2, s9]. The evidence base is largely limited to Russian-language studies with small sample sizes and preclinical animal and cell studies [s1, s4, s7].
Legal Status (DE)
In Germany, Selank is neither approved as a medicinal product nor marketable as a food supplement. It is an unapproved substance with unresolved medicinal product status under the AMG (Medicinal Products Act). Personal possession and purchase occupy a legal grey area; commercial marketing as a medicinal product without approval is illegal. The Anti-Doping Act (AntiDopG) does not currently apply to Selank, as it is not listed in the relevant annex [s10, s11]. In Russia, Selank has been approved as a medicinal product for anxiety disorders since the late 2000s [s2].
Mechanism of Action
Selank acts simultaneously via multiple neurotransmitter systems [s7]: 1. GABAergic modulation: Selank allosterically modulates GABA-A receptors, thereby enhancing inhibitory neuronal signaling, similarly to benzodiazepines but without directly binding to the benzodiazepine binding site [s4, s7]. Gene expression analyses showed that Selank influences the expression of GABAergic neurotransmission genes [s4]. 2. Enkephalin stabilization: Selank inhibits the enzymatic hydrolysis of plasma enkephalins (endogenous opioid peptides), thereby prolonging their duration of action. This contributes to anxiety and stress reduction [s8, s12]. 3. Monoamine regulation: Selank regulates the concentrations of serotonin, dopamine, and noradrenaline in the brain, influencing mood, anxiety, and cognitive performance [s8]. Animal studies indicate that nootropic activity is linked to serotonin metabolism [s6]. 4. BDNF expression: Cell studies have shown that Selank influences the expression of Brain-Derived Neurotrophic Factor (BDNF), which may explain neurotrophic effects [s7]. 5. Immunomodulation: Selank modulates IL-6 expression and the cytokine profile of T-helper cells, implying anti-inflammatory properties [s5]. 6. Amygdala connectivity: A neuroimaging finding (intranasal application) demonstrated altered resting-state connectivity between the right amygdala and temporal cortex within 20 minutes of administration, consistent with the anxiolytic mechanism [s12].
Dosing
Angstreduktion (intranasal)
- Dose
- 250–500 mcg per application
- Frequency
- 1–3× täglich
- Route
- intranasal
- Duration
- 10–14 Tage (typische russische Protokolldauer)
- Timing
- Morning and/or evening; midday if needed
- With food
- optional
Kognitive Unterstützung (intranasal)
- Dose
- 250 mcg daily
- Frequency
- 1× täglich morgens
- Route
- intranasal
- Duration
- 10 Tage
- Timing
- Morning fasted or with a light meal
- With food
- optional
Subkutan (Forschungsprotokoll)
- Dose
- 250–300 mcg per injection
- Frequency
- 1–2× täglich
- Route
- injektion-subkutan
- Duration
- Variabel; Langzeitdaten fehlen
- Timing
- Morning and evening; rotate injection sites
- With food
- optional
No officially established upper limit outside Russian studies. Russian clinical trials used up to 900 mcg/day intranasally [s1]. Higher doses are not covered by Western safety studies.
Nasal spray formulations typically deliver 100–150 mcg per actuation [s6]. Long-term safety over several weeks is not adequately established. Bacteriostatic water used for reconstituted lyophilizates should be consumed within 28 days of opening and stored under refrigeration.
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Nasenschleimhautreizung (bei intranasaler Applikation) Direct mechanical and chemical irritation of the nasal mucosa from intranasal administration; described in Russian studies [s1]. | gelegentlich | leicht |
| Leichte Kopfschmerzen Occasionally reported in community reports and safety data [s8, c2]. | gelegentlich | leicht |
| Müdigkeit / leichte Sedierung GABAergic modulation may be perceived as mild fatigue in some users; less pronounced than with benzodiazepines [s4, c2]. | selten | leicht |
| Fehlende Wirksamkeit (Non-Response) A subset of community users reports no perceptible effect, particularly with repeated use [c2, c3]. | gelegentlich | leicht |
| Psychoaktive Wirkung bei hohen Dosen (Euphorie, Enkaphalin-Effekte) At high doses, opioid effects may occur through enkephalin stabilization [c1]. | selten | moderat |
Contraindications
No safety data available for pregnancy and lactation; neuroactive peptides should not be used during this period [s8].
Selank is a structural analogue of tuftsin; allergic reactions to the parent molecule are possible [s3].
Additive GABAergic effects may cause excessive sedation or respiratory depression; no clinical data available for this combination [s4].
Absence of clinical data for these patient populations; interactions with antipsychotics and mood stabilizers unclear [s7].
No safety or efficacy data available for individuals under 18 years of age [s8].
Interactions
Synergistic
Frequently combined as a stack: Semax for cognitive activation, Selank for anxiolysis and mood stabilization. Both intranasal; administer 15–30 minutes apart [c1, c3].
BPC-157 supports the gut-brain axis and tissue regeneration, while Selank modulates the neurological stress response. Users report synergistic mood stabilization with this combination.
Cerebrolysin provides broad neurotrophic support, while Selank upregulates BDNF and improves emotional regulation. The mechanisms are complementary for cognitive and neuroprotective effects.
Both substances modulate GABAergic and serotonergic systems for anxiolysis and stress resilience. The combination may produce synergistic adaptogenic and anxiolytic effects.
Bacopa monnieri modulates serotonin, dopamine, and the cholinergic system, while Selank influences serotonin, GABA, and BDNF. Both exhibit neuroprotective and mood-modulating properties.
Alpha-GPC increases acetylcholine levels and cholinergic activity; Selank improves cognitive function via BDNF and monoamine modulation. The combination addresses complementary neurotransmitter systems.
Citicoline supports cell membranes and neurotransmitter production via phosphorylcholine; Selank improves neuroplastic and anxiolytic parameters. Both are complementary for comprehensive cognitive support.
Dihexa promotes synaptogenesis via HGF/c-Met; Selank enhances BDNF and reduces emotional stress burden. The combination is used in nootropic protocols for comprehensive cognitive optimization.
Caution
Additive GABAergic inhibition; risk of excessive sedation and respiratory depression [s4].
Selank may modulate BDNF expression and the GABAergic effects of olanzapine; clinical significance unclear [s7].
Animal studies demonstrate Selank influence on alcohol-related behaviors; additive CNS depression possible [s12].
Enkephalin stabilization by Selank could potentiate opioid-like effects; mechanistic interaction possible [s8].
Studies
Tier A — High Evidence
Outcome: Anxiolytic efficacy in GAD and neurasthenia vs. medazepam (Hamilton, Zung, CGI scales)
Effect Size: Comparable anxiolytic effect to medazepam; better tolerability; no precise effect sizes in available data
Outcome: Immunotropic effects: IL-6 gene expression in peripheral blood leukocytes in anxiety-asthenic patients
Effect Size: 10⁻⁷ M Selank completely suppressed IL-6 gene expression in vitro; in vivo effect size not quantified
Tier B — Moderate Evidence
Outcome: Expression of GABAergic neurotransmission genes in IMR-32 neuroblastoma cells following Selank administration
Effect Size: Significant changes in gene expression of GABA receptor subunits and BDNF
Outcome: Memory consolidation, serotonin metabolism, and nootropic activity
Effect Size: Significant improvement in memory consolidation when injected during the consolidation phase
Tier C — Low Evidence
Outcome: GABA, Selank, and olanzapine – effects on GABAergic genes in IMR-32 cells, BDNF modulation
Effect Size: Selank modulates olanzapine effect via BDNF influence; qualitative gene expression changes
Community Evidence
Top reported benefits
- Marked anxiety reduction and emotional stabilization
- Enhanced mental clarity and calm focus
- No dependence potential compared to benzodiazepines
- Mild improvement in sleep quality
- Stress resilience in daily life
Top reported issues
- Effect diminishes with repeated use (tachyphylaxis in individual users)
- Nasal mucosa irritation with prolonged intranasal use
- Unreliable effect – not all users respond
- Quality differences between suppliers difficult to assess
Individual users report very strong, near-euphoric effects at higher doses, attributed to enkephalin stabilization [c1]. The lack of quality control in grey-market products is discussed as a relevant safety risk. Long-term experiences spanning several months are rarely documented.
Scientific Sources
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Zozulia AA, Neznamov GG, Siuniakov TS, et al. (2008). Zhurnal Nevrologii i Psikhiatrii imeni S.S. KorsakovaBPMID:18454096 - Peptide legal in Deutschland? Rechtslage 2026
Peptide Culture Editorial Team (2026). peptide-culture.comDLink - Peptide / Research Chemicals – Strafbarkeit in Deutschland
die-anwalts-kanzlei.de (2024). die-anwalts-kanzlei.deDLink - Selank and Serotonin: Neurotransmitter Effects on Multiple Neurotransmitter Systems
RethinkPeptides Editorial Team (2024). rethinkpeptides.comDLink - Functional Connectomic Approach to Studying Selank and Semax Effects
Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Myasoedov NF (2020). Doklady Biological SciencesCPMID:32342318DOI - Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
Vyunova TV, Andreeva LA, Myasoedov NF (2018). Current Medicinal ChemistryCPMID:30255741DOI - Comparison of pharmacological effects of heptapeptide Selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice
Inozemtsev AN, Bokieva SB, Kovalev GI, Nadorova AV, Kruglov SV (2018). Eksperimental'naia i Klinicheskaia FarmakologiiaCPMID:29787664 - The Influence of Selank on the Level of Cytokines Under the Conditions of 'Social' Stress
Kasian AS, Andreeva LA, Unichenko PS, Kolomin TA, Myasoedov NF, Khazipov RN (2020). Current Molecular PharmacologyCPMID:32621722DOI - A comparison of the anxiolytic effect and tolerability of selank and phenibut in patients with generalized anxiety disorder
Akhapkin RV, Avedisova AS, Verigo NI, et al. (2014). Zhurnal Nevrologii i Psikhiatrii imeni S.S. KorsakovaBPMID:25176261 - Selank – Comprehensive Research Monograph: Pharmacological Profile and Tuftsin Analogy
Monis A, Maple K (2024). Medical Anti-Aging (White Paper)CLink - Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Volkova A, Shadrina M, Kolomin T, et al. (2016). PLOS ONECDOI - Immunomodulatory effects of selank in patients with anxiety-asthenic disorders
Uchakina ON, Uchakin PN, Miasoedov NF, et al. (2008). Zhurnal Nevrologii i Psikhiatrii imeni S.S. KorsakovaCPMID:18577961 - Experimental optimization of learning and memory processes by selank
Semenova TP, Kozlovskaia MM, Zakharova NM, et al. (2010). Eksperimental'naia i Klinicheskaia FarmakologiiaCPMID:20919548 - GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Shadrina M, Kolomin T, Agapova T, et al. (2017). Frontiers in PharmacologyCDOI - Die Wissenschaft hinter Selank: Pharmakologische Eigenschaften und aktuelle Forschung
nbinno.com Editorial Team (2024). nbinno.com (Industriewebseite)DLink - Selank Peptide: Regulatory Status – Not FDA- or EMA-Approved
Pinnacle Peptides Editorial Team (2024). pinnaclepeptides.comDLink
Community Sources
Storage
Unopened
Store lyophilized powder at -20 °C, protected from light and moisture. Shelf life per manufacturer specifications (typically 24 months).
Opened
After reconstitution with bacteriostatic water, store under refrigeration (2–8 °C) and consume within 28 days.
Notes
Store prepared nasal spray solutions at 2–8 °C; avoid freezing. Avoid repeated freeze-thaw cycles of the reconstituted peptide, as this reduces potency.